4 noviembre 2014
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer if they simultaneously received an immune stimulant.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/JRhVFzHGXmU/141104163023.htm
